ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Study: 21% of Transvaginal Mesh Patients Needed Surgery Again


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

women prepping for surgery

Almost one-third of patients who had transvaginal mesh surgery needed surgery again, a new study revealed.

The study followed women for up to 25 years after transvaginal prolapse repair with synthetic mesh. More than 20 percent of the women reported having to undergo a later surgery.

Women more likely to need another surgery included:

  • Younger women
  • Women with apical mesh placed
  • Women who experienced urinary tract injury during the surgery

16% of Patients ‘Very Unsatisfied’ with Transvaginal Mesh Surgery Results

Researchers collected medical information and data from patients’ medical records.

The patients in the study had vaginal prolapse surgery using synthetic mesh. The surgeries took place between May 1991 and October 2010.

Injured by complications related to transvaginal mesh? Get a Free Case Review

Researchers used written surveys and pelvic exams to assess patients’ symptoms. They also evaluated patients’ satisfaction with the surgery.

Among 804 possible patients, 158 were eligible for inclusion in the study.

A total of 54 patients — or 34 percent — experienced mesh-related complications.

Thirty-three patients — or 21 percent — needed another operation.

Researchers received 43 questionnaires ranking patient satisfaction.

  • 16 percent reported that their symptoms became worse after surgery
  • 42 percent were “very satisfied” with their surgical results
  • 16 percent were “very unsatisfied”

Authors of the study shared the results at a Society of Urodynamics meeting in Austin, Texas.

The conference focused on female pelvic medicine and urogenital reconstruction. It took place over a period of five days from Feb. 27 to March 3, 2018.

Kristin Compton
Written By Kristin Compton Writer

Kristin Compton's background is in legal studies. She worked as a paralegal before joining Drugwatch as a writer and researcher. She was also a member of the National Association of Legal Assistants. A mother and longtime patient, she has firsthand experience of the harmful effects prescription drugs can have on women and their children. Some of her qualifications include:

  • Bachelor of Arts in Legal Studies | Pre-Law from University of West Florida
  • Past employment with The Health Law Firm and Kerrigan, Estess, Rankin, McLeod & Thompson LLC
  • Personal experience battling severe food allergies, asthma and high-risk pregnancies
Edited By
Emily Miller
Emily Miller Managing Editor

1 Cited Research Article writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Farhan, B., MD, (2018). SUFU 2018: Meshing Around: Long-Term Outcomes Following Vaginal Reconstructive Surgery with Synthetic Mesh Augmentation. Uro Today. Retrieved from
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(877) 312-3413